Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 357

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 357
---
 in the lab without degradation concerns Thus, miRNAs from the brain can be interrogated using a routine blood sample. Early, Specific Detection of MCI and AD MCI and AD Both the number of AD patients and the number of people at risk for developing AD are growing rapidly, especially in the developed countries, in part due to increased lifespan. Early diagnosis and intervention are keys to developing more effective treatment, or potentially prevention, of AD. Alzheimer’s Association Report: 2025 Alzheimer’s Disease Facts and Figures ( https://www.alz.org/media/documents/alzheimers -facts-and-figures .pdf) provides the following statistics: •An estimated 7.2 million Americans age 65 and older are living with Alzheimer’s in 2025. Seventy -fourpercent are age 75 or older. •About 1 in 9 people age 65 and older (11%) has Alzheimer’s. •Almost two -thirdsof Americans with Alzheimer’s are women. 201 •Older Black Americans are about twice as likely to have Alzheimer’s or other dementias as older Whites. •Older Hispanics are about one and one -halftimes as likely to have Alzheimer’s or other dementias as older Whites. •People younger than 65 can also develop Alzheimer’s dementia. Although prevalence studies are limited, researchers believe about 110 of every 100,000 people age 30 to 64 years, or about 200,000 Americans in total, have younger -onsetdementia. •Someone in the US develops AD every 67 seconds and by 2050 one new case of AD is expected to develop every 33 seconds (~1M new cases per year); •Deaths due to Alzheimer’s disease between 2000 and 2019 have more than doubled, increasing 145%. •Among people aged70, 61% of those with Alzheimer’s dementia are expected to die before age80, compared with 30% of people without Alzheimer’s dementia. •This results in a significant cost burden to families, and payors such as Medicare and Medicaid: •In 2025, total payments for all individuals with Alzheimer’s disease or other dementias are estimated at $384 billion (not including unpaid caregiving). •Medicare and Medicaid are expected to cover $245 billion, or 64%, of the total health care and long -termcare payments for people with Alzheimer’s disease or other dementias. Out -of-pocketspending is expected to be around $97B